Alnylam Picks PCSK9 Cholesterol Drug As Newest Candidate, Shelving apoB | GenomeWeb
Alnylam Pharmaceuticals announced this week that it has added its preclinical hypercholesterolemia program targeting proprotein convertase subtilisn/kexin type 9, or PCSK9, to its formal development pipeline.
The company also said it expects that one of the two investigational new drug applications it intends to file next year will be for a PCSK9-targeting therapeutic, which would be Alnylam’s first systemically delivered RNAi drug candidate.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.